[{"id":16088,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/affilogic-2\/","name":"affilogic-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-35.png","alt":""},"title":"Affilogic","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:51:36","modifiedDate":"2026-04-17 11:26:54","modifiedDateGMT":"2026-04-17 15:26:54","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":4},"status":"publish","excerpt":"Affilogic is a private biotech company specialized in discovering and developing affinity proteins Nanofitins\u00ae through early-stage collaborations with worldwide industry leaders in the pharmaceutical sector."},{"id":16619,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/algenscribe-2\/","name":"algenscribe-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-47.png","alt":""},"title":"Algenscribe","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 27, 2026","dateGMT":"2026-04-27 17:58:52","modifiedDate":"2026-04-27 14:00:36","modifiedDateGMT":"2026-04-27 18:00:36","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":33},"status":"publish","excerpt":"Algenscribe is a pre-clinical stage biotechnology company developing a first-in-class Gene Replacement platform. The flexible platform aims to improve the efficiency and quality of Gene Editing from single bases to multi-kilobase replacements."},{"id":16315,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/antelope-therapeutics\/","name":"antelope-therapeutics","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image26.png","alt":""},"title":"Antelope Therapeutics","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:51:26","modifiedDate":"2026-04-17 11:22:14","modifiedDateGMT":"2026-04-17 15:22:14","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":58},"status":"publish","excerpt":"Antelope Therapeutics is a preclinical-stage oncology company developing ATL-024, a novel Antibody-Drug Conjugate (ADC) against a first-in-class target for the treatment of colorectal and pancreatic cancers. These two diseases cause nearly 400,000 deaths annually across the 7MM and represent a multi-billion-dollar market opportunity."},{"id":16086,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/aurobac-therapeutics-2\/","name":"aurobac-therapeutics-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-40.png","alt":""},"title":"AUROBAC THERAPEUTICS","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:51:52","modifiedDate":"2026-03-31 16:55:34","modifiedDateGMT":"2026-03-31 20:55:34","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":58},"status":"publish","excerpt":"AUROBAC THERAPEUTICS is a biopharmaceutical company established in 2022 through a strategic partnership between three global leaders in life sciences innovation: Boehringer Ingelheim, Evotec and bioM\u00e9rieux. AUROBAC is dedicated to tackling urgent and unmet medical needs in the treatment of bacterial infections and their consequences in acute hospital settings, with a strong focus on the escalating threat of antimicrobial resistance (AMR)."},{"id":16385,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/brenus-pharma-2\/","name":"brenus-pharma-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-63.png","alt":""},"title":"Brenus Pharma","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 15, 2026","dateGMT":"2026-04-15 17:33:41","modifiedDate":"2026-04-27 11:38:08","modifiedDateGMT":"2026-04-27 15:38:08","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":12},"status":"publish","excerpt":"Brenus Pharma is a French clinical-stage biotechnology company developing a new class of in vivo immunotherapies for solid tumors. The company has built a proprietary, data-driven platform based on its Stimulated-Ghost-Cell (SGC) technology. It transforms tumor complexity into scalable, off-the-shelf therapeutic candidates by integrating multi-omics data, predictive validation models, and GMP-ready manufacturing. This approach enables cost control and broad patient access, overcoming key limitations of personalized therapies such as mRNA and CAR-T."},{"id":16476,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/cenexi-2\/","name":"cenexi-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/azdazdazdaz.png","alt":""},"title":"CENEXI","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 31, 2026","dateGMT":"2026-03-31 13:55:44","modifiedDate":"2026-04-08 14:11:15","modifiedDateGMT":"2026-04-08 18:11:15","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":39},"status":"publish","excerpt":"CENEXI is a CDMO for drug products,specializing in compounding, fill and finish of injectables (vials, lyo, pre-filled syringes and ampoules), hormonal and desensitzing tablets. Cenexi provides industrial develompment and scale-up for commercial products, as well as clinical batches for Phases 1,2 and 3. Drugs substances compounded and filled are: biologicals, vaccines, MabS, ADC, high-potent, sex hormones and regular products."},{"id":16386,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/ceres-brain-therpeutics\/","name":"ceres-brain-therpeutics","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-41-1.png","alt":""},"title":"Ceres Brain Therpeutics","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-17 03:41:18","modifiedDate":"2026-04-16 23:41:19","modifiedDateGMT":"2026-04-17 03:41:19","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":18},"status":"publish","excerpt":"Ceres Brain Therapeutics is a biotechnology company advancing CBT101, a novel central nervous system (CNS) therapeutic candidate that has recently progressed into Phase 2 clinical development. CBT101 is positioned to address major unmet needs in severe neurological diseases through a differentiated, indication specific approach to neuronal energy dysfunction."},{"id":16087,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/covalab-3\/","name":"covalab-3","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image23.png","alt":""},"title":"Covalab","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:51:47","modifiedDate":"2026-03-31 16:55:47","modifiedDateGMT":"2026-03-31 20:55:47","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/services\/\" rel=\"category tag\">Services<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/services\/\" rel=\"category tag\">Services<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":57},"status":"publish","excerpt":"Founded in 1995, Covalab is a French biotechnology company renowned for its expertise in antibody engineering. With over three decades of experience, Covalab specializes in the design and development of a wide range of antibodies, including polyclonal, monoclonal, scFv, FAb, VHH, and recombinant antibodies, utilizing advanced techniques such as DNA immunization."},{"id":16969,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/curlim\/","name":"curlim","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Logo-curlim-HQ.png","alt":""},"title":"Curlim","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-16 19:48:21","modifiedDate":"2026-04-16 16:24:16","modifiedDateGMT":"2026-04-16 20:24:16","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":18},"status":"publish","excerpt":"Based in France, Curlim is an innovative biotech company focused on developing therapeutic solutions for hereditary peripheral neuropathies and rare neurodegenerative diseases. These debilitating conditions, such as Charcot\u2013Marie\u2013Tooth disease (CMT), affect tens of thousands of patients in Europe and the U.S. and currently have no curative treatments. CMT, the most common inherited peripheral neuropathy, affects approximately 1 in 5,000 individuals worldwide representing a major unmet medical need for patients worldwide."},{"id":16805,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/deeptope\/","name":"deeptope","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-20-1.png","alt":""},"title":"Deeptope","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 19:49:41","modifiedDate":"2026-04-07 15:49:42","modifiedDateGMT":"2026-04-07 19:49:42","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":45},"status":"publish","excerpt":"Deeptope's offer consists in characterizing antigen \/ antibody interactions (epitope \/ paratope mapping) and optimizing antibodies (they can also work on many other protein-protein interactions and corresponding protein optimizations)."},{"id":16381,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/_dolinnov\/","name":"_dolinnov","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image2reg.png","alt":""},"title":"DOLINNOV","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 19:20:06","modifiedDate":"2026-04-07 15:21:00","modifiedDateGMT":"2026-04-07 19:21:00","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":1},"status":"publish","excerpt":"Dolinnov develops a first-in-class non-opioid therapy for chronic pain, one of the largest unmet medical needs worldwide. Despite recent progress, current approaches targeting single ion channels (Nav1.7, Nav1.8) face key limitations due to redundancy, as other channels can compensate over time, limiting long-term efficacy."},{"id":15832,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/exeliom-biosciences-2\/","name":"exeliom-biosciences-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image13.png","alt":""},"title":"EXELIOM BIOSCIENCES","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 19, 2026","dateGMT":"2026-03-19 15:25:07","modifiedDate":"2026-04-17 11:18:07","modifiedDateGMT":"2026-04-17 15:18:07","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":10},"status":"publish","excerpt":"Exeliom Biosciences is a clinical-stage immunotherapy company developing a first-in-class oral innate immune modulator designed to enhance the efficacy and durability of immune checkpoint inhibitors (ICIs). Its lead asset, EXL01, selectively activates the non-canonical NOD2\u2013CARD9 signaling axis, reprogramming tumor-associated macrophages from an immunosuppressive to an antigen-presenting, T-cell\u2013supportive state."},{"id":15884,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/h-a-c-pharma-2\/","name":"h-a-c-pharma-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-8.png","alt":""},"title":"H.A.C PHARMA","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:52:42","modifiedDate":"2026-03-31 11:41:14","modifiedDateGMT":"2026-03-31 15:41:14","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":0},"status":"publish","excerpt":"Founded in 2007, H.A.C. Pharma is a private, PE-backed European specialty pharmaceutical platform dedicated to delivering therapies for patients facing conditions with limited treatment options.\nH.A.C. Pharma has earned the trust of international partners by licensing or acquiring, registering, and commercializing their medicines across Europe. This successful track record is built on a structured approach involving healthcare professionals, medical societies, and regulatory authorities to ensure optimal patient access."},{"id":16972,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/hephaistos\/","name":"hephaistos","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-40-1.png","alt":""},"title":"HEPHAISTOS","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-16 20:11:22","modifiedDate":"2026-04-16 16:13:50","modifiedDateGMT":"2026-04-16 20:13:50","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":18},"status":"publish","excerpt":"HEPHAISTOS is a preclinical-stage biopharmaceutical company focused on designing and developing a third-generation innate immune activator. Its mission is to address a major challenge in oncology: improving patient responses to existing immunotherapies by overcoming myeloid-driven tumor immunosuppression."},{"id":16807,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/igyxos\/","name":"igyxos","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-22-1.png","alt":""},"title":"Igyxos","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 20:47:10","modifiedDate":"2026-04-07 16:47:11","modifiedDateGMT":"2026-04-07 20:47:11","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":26},"status":"publish","excerpt":"Igyxos is a French biotechnology company dedicated to addressing the growing global need for improved infertility solutions through novel therapeutics that make treatment more effective and efficient for men and women. Igyxos lead asset is IGX12, a first-in-class humanized monoclonal antibody which is Phase 2 ready."},{"id":16382,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/inspek\/","name":"inspek","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image3-1.png","alt":""},"title":"InSpek","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 27, 2026","dateGMT":"2026-03-27 14:59:42","modifiedDate":"2026-04-27 13:38:50","modifiedDateGMT":"2026-04-27 17:38:50","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":20},"status":"publish","excerpt":"InSpek is a biotools company redefining bioprocess manufacturing through real-time monitoring and artificial intelligence. Its bioprocess optimization platform doesn't just analyse data \u2014 it collects it, thanks to proprietary photonic sensing technology developed at MIT and CNRS. On-chip optical sensors capture rich, multimodal process data at any scale, directly within bioreactors, without sampling and without contamination risk. This fuels AI and chemometric models that learn process dynamics, detect anomalies, and identify optimal operating conditions \u2014 enabling higher yields, lower costs, and faster scale-up."},{"id":15849,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/lys-therapeutics-2\/","name":"lys-therapeutics-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-39.png","alt":""},"title":"LYS THERAPEUTICS","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:52:51","modifiedDate":"2026-03-31 16:52:48","modifiedDateGMT":"2026-03-31 20:52:48","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":57},"status":"publish","excerpt":""},{"id":16664,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/mabsilico-2\/","name":"mabsilico-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-65.png","alt":""},"title":"MAbSilico","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 27, 2026","dateGMT":"2026-04-27 17:47:53","modifiedDate":"2026-04-27 13:50:34","modifiedDateGMT":"2026-04-27 17:50:34","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":38},"status":"publish","excerpt":"MAbSilico is a premier TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. They empower biotech and pharmaceutical companies to significantly leverage antibody discovery risks by providing high-potential computational candidates in just a matter of days. These candidates are meticulously designed and characterized in silico and subsequently validated with state-of-the-art biological technologies, ensuring a seamless transition from digital modeling to laboratory success. By combining sophisticated 3D modeling, complex interaction simulations, and advanced linear sequence analysis, MAbSilico defines antibody drug candidates through a rigorous assessment of their epitope, affinity, off-target risk, cross-species reactivity, and developability, ensuring they are fully prepared for biological activity evaluation."},{"id":16640,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/__trashed-40\/","name":"__trashed-40","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-27.png","alt":""},"title":"Medincell","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 19:22:38","modifiedDate":"2026-04-08 09:55:25","modifiedDateGMT":"2026-04-08 13:55:25","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":27},"status":"publish","excerpt":"Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas. Its innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact."},{"id":16954,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/netris-pharma-2\/","name":"netris-pharma-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-40.png","alt":""},"title":"Netris Pharma","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 16, 2026","dateGMT":"2026-04-16 16:16:00","modifiedDate":"2026-04-23 10:14:16","modifiedDateGMT":"2026-04-23 14:14:16","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":29},"status":"publish","excerpt":"Netris Pharma was founded by the pioneers of Dependence Receptors and its mission is to provide cancer patients with new treatment solutions able to overcome resistance to chemo- and Immunotherapies. The company is currently developing NP137, a first-in-class monoclonal antibody targeting Netrin1, a new untapped oncology target aberrantly expressed in multiple tumor types. Netrin1 has been showed to promote Epithelial-Mesenchymal Transition (EMT) and by disrupting the binding of Netrin1 to its receptors, NP137 is arguably the first compound able to break the deadlock of EMT to reduce metastasis and block resistance to cancer treatment. The product benefits from an excellent safety profile in monotherapy and in combination, and has already shown signs of antitumoral activity. In particular, the LAPNET study of NP137 in combination with mFolfirinox in Pancreatic cancer patients revealed neogenin as a potential predictive biomarker and opened a path for a biomarker-driven development in PDAC. Beyond PDAC, interim efficacy data in HNSCC and HCC further illustrate the potential of the product across solid tumors and strengthen the committment to advance NP137 as a new treatment option to address patient populations with high unmet medical need."},{"id":16808,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/nfl-biosciences-2\/","name":"nfl-biosciences-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-23.png","alt":""},"title":"NFL Biosciences","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 21:04:15","modifiedDate":"2026-04-07 17:04:16","modifiedDateGMT":"2026-04-07 21:04:16","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":56},"status":"publish","excerpt":"NFL Biosciences is a Phase 3 french public biotech company (ticker ALNFL), developing NFL-101 and NFL-102, disruptive drug candidates for smoking cessation with a new and distinctive mechanism of action."},{"id":16477,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/oncodesign-precision-medecine\/","name":"oncodesign-precision-medecine","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/zefsqqfs.png","alt":""},"title":"Oncodesign Precision Medecine","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 31, 2026","dateGMT":"2026-03-31 14:05:24","modifiedDate":"2026-03-31 16:38:46","modifiedDateGMT":"2026-03-31 20:38:46","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":40},"status":"publish","excerpt":"Oncodesign Precision Medicine (OPM), founded in 2022, is a biopharmaceutical company specializing in precision medicine, dedicated to discovering treatments for resistant and metastatic cancers. OPM currently has two kinase inhibitors preparing for Phase 2 clinical phases in patients: OPM-101, a RIPK2 inhibitor has demonstrated a significant therapeutic margin and absence of toxicity in its phase I healthy volunteers study. The compound is ready to start a Phase 1b\/2a in few months aiming at reverting resistance in advanced melanoma patients not\/no longer responding to PD1 checkpoint inhibitors. OPM\u2019s RIPK2 inhibitors also hold significant potential in inflammatory diseases (IBD)."},{"id":16083,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/owkin-2\/","name":"owkin-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2024\/04\/Logos-site-BIO-2024-Entreprises-14.png","alt":""},"title":"Owkin","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:52:15","modifiedDate":"2026-03-31 16:54:30","modifiedDateGMT":"2026-03-31 20:54:30","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/services\/\" rel=\"category tag\">Services<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/services\/\" rel=\"category tag\">Services<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":39},"status":"publish","excerpt":"Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biological Artificial Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster."},{"id":16084,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/sequens\/","name":"sequens","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image20.png","alt":""},"title":"SEQUENS","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:52:21","modifiedDate":"2026-03-31 11:42:13","modifiedDateGMT":"2026-03-31 15:42:13","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/cro-cdmo\/\" rel=\"category tag\">CRO\/CDMO<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":49},"status":"publish","excerpt":"SEQENS is a global leader in the pharmaceutical industry, with over 30 years' experience in the development and manufacturing of APIs, intermediates and polymers. Seqens\u2019 state-of-the-art R&D facilities in Europe and in the US, along with its network of 8 manufacturing sites (GMP and non\u2011GMP), enable the company to innovate, develop and industrialize the most demanding molecules and implement the best available technologies."},{"id":16616,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/_thea-open-innovation\/","name":"_thea-open-innovation","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/azdazd.png","alt":""},"title":"THEA OPEN INNOVATION","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 7, 2026","dateGMT":"2026-04-07 19:09:41","modifiedDate":"2026-04-07 15:09:51","modifiedDateGMT":"2026-04-07 19:09:51","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/medtech\/\" rel=\"category tag\">Medtech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/pharma\/\" rel=\"category tag\">Pharma<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":54},"status":"publish","excerpt":"Th\u00e9a Open Innovation (TOI) is the External innovation unit of Laboratoires Th\u00e9a, a family-owned, independent company fully dedicated to ophthalmology, operating in 75 countries including North America. Our mission is to identify and support the most promising developments in eye care, regardless of technology, through licensing agreements mainly."},{"id":16879,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/theremia\/","name":"theremia","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/04\/Design-sans-titre-32.png","alt":""},"title":"Theremia","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 14, 2026","dateGMT":"2026-04-14 14:14:09","modifiedDate":"2026-04-27 13:30:16","modifiedDateGMT":"2026-04-27 17:30:16","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":1,"sec":44},"status":"publish","excerpt":"Theremia is a precision medicine company specialized in neurology and psychiatry. Theremia develops explainable and causal AI models to help biotech and pharma companies de-risk and optimize drug development."},{"id":16388,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/_thx-pharma\/","name":"_thx-pharma","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image5-1.png","alt":""},"title":"THX Pharma","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Avr 13, 2026","dateGMT":"2026-04-13 19:46:58","modifiedDate":"2026-04-13 15:47:04","modifiedDateGMT":"2026-04-13 19:47:04","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":41},"status":"publish","excerpt":"THX Pharma (ALTHX) is a listed biopharmaceutical company dedicated to discovering and developing treatments for rare neurological disorders. THX pharma has two lead assets TX01 and Batten-1:"},{"id":16079,"link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/whitelab-genomics-2\/","name":"whitelab-genomics-2","thumbnail":{"url":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/wp-content\/uploads\/sites\/1378\/2026\/03\/Image10.png","alt":""},"title":"WhiteLab Genomics","postMeta":[],"author":{"name":"araymond","link":"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/author\/araymond\/"},"date":"Mar 25, 2026","dateGMT":"2026-03-25 20:53:02","modifiedDate":"2026-04-22 15:45:26","modifiedDateGMT":"2026-04-22 19:45:26","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a>, <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>","space":"<a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/2026\/\" rel=\"category tag\">2026<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/biotech\/\" rel=\"category tag\">Biotech<\/a> <a href=\"https:\/\/event.businessfrance.fr\/business-france-at-bio-convention\/category\/techbio\/\" rel=\"category tag\">TechBio<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":0,"sec":47},"status":"publish","excerpt":"WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y-Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks."}]